Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.
about
Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleasesA human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infectionCells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface displayPopulation pharmacokinetic analysis of panitumumab in patients with advanced solid tumorsHigh-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH regionGeneration of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytesNanobodies as novel agents for cancer therapy.Recombinant antibodies: a novel approach to cancer diagnosis and therapy.Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsisThe immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsOverview on the use of therapeutic antibodies in drug discovery.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesGeneration of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potentialYeast Display-Based Antibody Affinity Maturation Using Detergent-Solubilized Cell Lysates.An antidote for acute cocaine toxicity.Monoclonal antibodies for brain tumour treatment.Clinical development of anti-RANKL therapyRecent developments in the production of human therapeutic proteins in eukaryotic algae.Opinion: antibody-based therapies for malaria.Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.Understanding and making use of human memory B cells.Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individualsReceptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Metastatic colorectal cancer-past, progress and futurePharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibodyTherapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.Role of denosumab in breast cancer.Therapeutic targeting of osteoclast function and pathways.Engineering the variable region of therapeutic IgG antibodies.Monoclonal antibodies based on hybridoma technology.In situ production of therapeutic monoclonal antibodies.Stable antibody expression at therapeutic levels using the 2A peptide.Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain.Characterization of Entamoeba histolytica intermediate subunit lectin-specific human monoclonal antibodies generated in transgenic mice expressing human immunoglobulin loci.Studies towards the improvement of an anti-cocaine monoclonal antibody for treatment of acute overdose.Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.
P2860
Q21089956-4EE544A1-84AD-4F6D-91F2-1E53F68B8A42Q24672825-2E70A950-854F-4235-960B-582F30F9E08FQ26849777-2C2D338D-C597-4D1F-82DF-64FB73610145Q28257098-308C91AB-5155-4343-848B-689783F729FBQ28709119-E6524A7A-0187-4CD2-B2E6-179875BF3343Q30352589-ACD4B3A1-C029-45AF-9D6B-C99FFDD655EDQ30778309-3A3AFF60-ECDD-4E5A-A599-4B1C18F4E99BQ33181384-EF70285F-E97B-4D01-93F8-86546FBA398DQ33220467-E2352305-E667-4CF1-A807-02A8F3E54869Q34006764-B1B39A57-F21F-4440-8342-DD391DA46D92Q34110768-65217AF0-43AA-4643-88E3-C4DC784BEC90Q34147273-625B376B-9FC7-4195-957A-B1139332D52CQ34273411-8A53D2B1-C2D2-415F-8E82-090A372D609FQ34536782-A23097C0-2F17-45E7-9C78-D6CD1945FE67Q35047652-E37A556F-951F-4516-8CF1-0E39825E72F8Q35659193-675D3428-4C8F-45F0-B5FB-CC392D66A8C3Q35869933-AD147F2C-0DDF-45A5-A44E-728DC358056EQ35873775-2DF02849-59CF-4A80-B78F-7A213C7ABB70Q35901092-36068B6E-3AB0-4043-BF7A-D986F064B201Q36065964-C53A2B5F-D70C-4269-8141-DBC0CC1DEA1FQ36302325-A4A50922-D800-41D9-B56D-F4C2929BE7F4Q36391426-FAA60FC9-6A38-436B-BF29-4734462A9CC6Q36411841-2CC9FA41-FF3D-4CC2-9ADF-E7E4A2875D81Q36478827-2447773A-3C45-4C6E-85E5-82B4954AC112Q36529030-F23B5F6C-4468-47B5-A70D-9C3AA310BD82Q36646919-E979359F-3DF0-4912-808B-DA0F8824B729Q36860987-6D11D457-90AF-4517-9A4A-6BF8A70DA438Q36893806-EFDA189F-C15E-47D3-BFF4-561ACA1E4545Q37230907-F1CBB9EB-FF89-4087-A230-55A2772EEFB0Q37409192-31CA9A83-52DE-4EF2-9572-DACEBA7768F0Q37571986-0F0444A1-89F2-430B-B992-898AD29F5471Q37825905-F2277A37-F549-47B3-9577-902363F8EB9FQ37853324-93F1E2B6-6558-4B7B-A396-687BCAC2816DQ38162972-2D5A485D-661A-450C-A1AD-0C046F1588F2Q38314210-65E25798-37CB-4BE2-824F-DC667770D51BQ40434248-DE38DB7B-F5C1-4DA6-9121-309C8D7B9F3EQ41762336-CD97D0A8-974B-4409-B592-59A4AED20EB3Q41858060-8B622984-343D-42A8-8BE5-C17E2AE62E69Q42387566-E3466290-3BE1-4405-B6C8-F8F832F2DD16Q52983334-BCBD34A4-6DB0-4F6E-8DA3-46575AB7F1DE
P2860
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antibody engineering via genet ...... c human monoclonal antibodies.
@ast
Antibody engineering via genet ...... c human monoclonal antibodies.
@en
type
label
Antibody engineering via genet ...... c human monoclonal antibodies.
@ast
Antibody engineering via genet ...... c human monoclonal antibodies.
@en
prefLabel
Antibody engineering via genet ...... c human monoclonal antibodies.
@ast
Antibody engineering via genet ...... c human monoclonal antibodies.
@en
P1476
Antibody engineering via genet ...... c human monoclonal antibodies.
@en
P2093
P356
10.1016/S0022-1759(99)00137-4
P577
1999-12-01T00:00:00Z